c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside

SZTURZ, Petr, E. RAYMOND and S. FAIVRE. c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside. Oral oncology. AMSTERDAM: ELSEVIER SCIENCE BV, 2016, vol. 59, AUG 2016, p. "E12"-"E14", 3 pp. ISSN 1368-8375. Available from: https://dx.doi.org/10.1016/j.oraloncology.2016.05.017.

Basic information

• Original name: c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside
• Authors: SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), E. RAYMOND (250 France) and S. FAIVRE (250 France).
• Edition: Oral oncology, AMSTERDAM, ELSEVIER SCIENCE BV, 2016, 1368-8375.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 4.794
• RIV identification code: RIV/00216224:14110/16:00090826
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1016/j.oraloncology.2016.05.017
• UT WoS: 000380544000005
• Keywords in English: squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo
• Tags: EL OK
• Tags: International impact, Reviewed

Abstract

Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis.